Premium
Validation of a sample pretreatment protocol to convert a drug‐sensitive into a drug‐tolerant anti‐infliximab antibody immunoassay
Author(s) -
Van Stappen Thomas,
Brouwers Els,
Vermeire Séverine,
Gils Ann
Publication year - 2017
Publication title -
drug testing and analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.065
H-Index - 54
eISSN - 1942-7611
pISSN - 1942-7603
DOI - 10.1002/dta.1968
Subject(s) - infliximab , drug , immunoassay , medicine , antibody , pharmacology , immunology , tumor necrosis factor alpha
A meta‐analysis revealed that up to 51% of patients treated with infliximab develop anti‐drug Abs (ADA) which are associated with loss of response. Detection of ADA is strongly influenced by assay technique since drug‐sensitive ADA assays are not able to detect ADA in the presence of drug and therefore underestimate ADA development. In addition, the lack of a calibrator antibody that can be used in a drug‐sensitive and drug‐tolerant assay hampers an adequate comparison among different assays. Here we present a sample pretreatment protocol to convert the bridging assay, originally developed as a drug‐sensitive assay, into a drug‐tolerant assay, allowing use of the same assay and calibrator antibody MA‐IFX10F9. Using the sample pretreatment protocol, the bridging assay detects antibodies towards infliximab in samples containing up to 5‐fold infliximab over anti‐infliximab. Analysis of consecutive serum samples from infliximab treated patients revealed that the drug‐tolerant assay detects ADA development up to 40 weeks earlier compared to the drug‐sensitive assay. In conclusion, the sample pretreatment protocol can be implemented in various assay formats and allows determination of ADA in the presence of drug, providing the possibility for early treatment optimization. Copyright © 2016 John Wiley & Sons, Ltd.